HDAC9 and breast neoplasm: These ER-α negative or tamoxifen/aromatase inhibitor-resistant breast tumors could be sensitized to anti-estrogen therapies by HDAC inhibitors that induce the expression of the epigenetically repressed ER-α receptor.